New Paper-Based Rapid Test for COVID-19 Awaiting FDA EUA Approval
By LabMedica International staff writers Posted on 30 Mar 2020 |
Image: Illustration of a 2019-novel coronavirus (nCoV) virion (Photo courtesy of Alissa Eckert, MS/CDC).
E25Bio (Cambridge, MA, USA), a startup company spun out from MIT (Cambridge, MA, USA), is developing a new rapid paper-based diagnostic test for COVID-18 that can deliver results in under half an hour. The test is based on technology developed at MIT’s Institute for Medical Engineering and Science (IMES) and will be submitted to the FDA for “emergency use authorization,” granting temporary approval for using the device on patient samples during public health emergencies.
For the past several years, IMES researchers have been working on diagnostic devices that operate like a pregnancy test but are able to identify viral proteins from patient samples. The technology, known as lateral flow technology, has been used by the researchers to develop tests for various infectious diseases, including Ebola, dengue fever, and Zika virus. The tests comprise strips of paper coated with antibodies that bind to a specific viral protein. A second antibody is attached to specialized nanoparticles while the patient’s sample is added to a solution of those particles. After this, the test strip is dipped in this solution. In case the viral protein is present, it attaches to the antibodies on the paper strip as well as the nanoparticle-bound antibodies, and a colored spot is visible on the strip in about 20 minutes. In addition to delivering rapid results, paper tests can also be easily and inexpensively manufactured in large quantities
“Our hope is that, similar to other tests that we’ve developed, this will be usable on the day that symptoms develop,” said Lee Gehrke, the Hermann L.F. von Helmholtz Professor at IMES who developed the technology behind the test. “We don’t have to wait for antibodies to the virus to come up.”
Related Links:
E25Bio
MIT
For the past several years, IMES researchers have been working on diagnostic devices that operate like a pregnancy test but are able to identify viral proteins from patient samples. The technology, known as lateral flow technology, has been used by the researchers to develop tests for various infectious diseases, including Ebola, dengue fever, and Zika virus. The tests comprise strips of paper coated with antibodies that bind to a specific viral protein. A second antibody is attached to specialized nanoparticles while the patient’s sample is added to a solution of those particles. After this, the test strip is dipped in this solution. In case the viral protein is present, it attaches to the antibodies on the paper strip as well as the nanoparticle-bound antibodies, and a colored spot is visible on the strip in about 20 minutes. In addition to delivering rapid results, paper tests can also be easily and inexpensively manufactured in large quantities
“Our hope is that, similar to other tests that we’ve developed, this will be usable on the day that symptoms develop,” said Lee Gehrke, the Hermann L.F. von Helmholtz Professor at IMES who developed the technology behind the test. “We don’t have to wait for antibodies to the virus to come up.”
Related Links:
E25Bio
MIT
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants